252 related articles for article (PubMed ID: 30520145)
101. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W;
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677
[TBL] [Abstract][Full Text] [Related]
102. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
103. Reversal of Alopecia Universalis by Tofacitinib: A Case Report.
Scheinberg M; Ferreira SB
Ann Intern Med; 2016 Nov; 165(10):750-751. PubMed ID: 27842401
[No Abstract] [Full Text] [Related]
104. Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients.
Jin T; Sun Z; Chen X; Wang Y; Li R; Ji S; Zhao Y
Dermatology; 2017; 233(2-3):164-169. PubMed ID: 28654918
[TBL] [Abstract][Full Text] [Related]
105. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
106. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Yamaoka K; Tanaka Y
Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
[TBL] [Abstract][Full Text] [Related]
107. A pilot study of tofacitinib for refractory Behçet's syndrome.
Liu J; Hou Y; Sun L; Li C; Li L; Zhao Y; Zeng X; Zhang F; Zheng W
Ann Rheum Dis; 2020 Nov; 79(11):1517-1520. PubMed ID: 32461206
[No Abstract] [Full Text] [Related]
108. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
109. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
110. Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Gómez-García F; Gómez-Arias PJ; Hernandez J; Montilla AM; Gay-Mimbrera J; Aguilar-Luque M; Viguera-Guerra I; Velez García-Nieto A; Isla-Tejera B; Ruano J
BMJ Open; 2019 May; 9(5):e028303. PubMed ID: 31122999
[TBL] [Abstract][Full Text] [Related]
111. Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response.
Sanchez-Diaz M; Diaz-Calvillo P; Rodriguez-Pozo JA; Tercedor-Sánchez J; Cantudo-Cuenca MR; Molina-Leyva A; Arias-Santiago S
Acta Derm Venereol; 2022 Jun; 102():adv00736. PubMed ID: 35578820
[No Abstract] [Full Text] [Related]
112. Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib.
Castillo R; Albayda J
Mod Rheumatol Case Rep; 2022 Jun; 6(2):199-202. PubMed ID: 35253877
[TBL] [Abstract][Full Text] [Related]
113. Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata.
Shin JM; Sung Y; Hong D; Jung KE; Seo YJ; Kim CD; Lee Y
J Dermatol Sci; 2024 Jun; 114(3):148-150. PubMed ID: 38734548
[No Abstract] [Full Text] [Related]
114. Disorders of Hypopigmentation.
Dina Y; McKesey J; Pandya AG
J Drugs Dermatol; 2019 Mar; 18(3):s115-s116. PubMed ID: 30909355
[TBL] [Abstract][Full Text] [Related]
115. Treatment of alopecia areata of the beard with baricitinib.
Moussa A; Eisman S; Sinclair RD; Bhoyrul B
J Am Acad Dermatol; 2023 Apr; 88(4):948-950. PubMed ID: 36427662
[No Abstract] [Full Text] [Related]
116. Tofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review.
Ma Y; Wang W; Shi D
Skin Res Technol; 2024 Jan; 30(1):e13553. PubMed ID: 38186061
[No Abstract] [Full Text] [Related]
117. New and Emerging Therapies for Alopecia Areata.
Pourang A; Mesinkovska NA
Drugs; 2020 May; 80(7):635-646. PubMed ID: 32323220
[TBL] [Abstract][Full Text] [Related]
118. Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib.
Berbert Ferreira S; Gavazzoni Dias MFR; Berbert Ferreira R; Neves Neto AC; Trüeb RM; Lupi O
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e411-e412. PubMed ID: 33587766
[No Abstract] [Full Text] [Related]
119. Treatment of longstanding alopecia areata universalis of the eyebrows/facial hair with oral and topical tofacitinib.
Gonzalez Matheus GA; Herat A
Dermatol Online J; 2022 Aug; 28(4):. PubMed ID: 36259869
[No Abstract] [Full Text] [Related]
120. Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
Youssef S; Lavian J; Lee EY; Fan W; Bordone LA
J Am Acad Dermatol; 2023 May; 88(5):1125-1127. PubMed ID: 35551958
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
